Fehr, Cassie
Klein, Karl Martin http://orcid.org/0000-0002-6654-1665
Article History
Accepted: 20 December 2021
First Online: 14 January 2022
Declarations
:
: C. Fehr declares that he has no competing interests. K. M. Klein reports personal fees from UCB Pharma, Novartis Pharma AG, Eisai, and GW Pharmaceuticals, grants from the federal state Hessen, Germany, through the LOEWE program and from the Canadian Institutes of Health Research.
: For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.